Trial Profile
Active-Controlled Trial of the Safety and Tolerability of MP29-02 in Subjects with Chronic Allergic or Nonallergic Rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2013
Price :
$35
*
At a glance
- Drugs Azelastine/fluticasone-propionate (Primary) ; Fluticasone propionate
- Indications Perennial allergic rhinitis; Rhinitis; Vasomotor rhinitis
- Focus Adverse reactions; Registrational
- Sponsors Meda Pharmaceuticals
- 06 Mar 2012 Results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 05 Mar 2012 Status changed from not stated to completed, according to a Meda media release.
- 31 May 2011 New trial record